0.74
-0.03(-3.90%)
Currency In USD
| Previous Close | 0.77 |
| Open | 0.77 |
| Day High | 0.79 |
| Day Low | 0.74 |
| 52-Week High | 65 |
| 52-Week Low | 0.3 |
| Volume | 225,069 |
| Average Volume | 4.5M |
| Market Cap | 6.61M |
| PE | 0.01 |
| EPS | 77.53 |
| Moving Average 50 Days | 0.76 |
| Moving Average 200 Days | 2.87 |
| Change | -0.03 |
If you invested $1000 in GRI Bio, Inc. (GRI) since IPO date, it would be worth $0.04 as of December 21, 2024 at a share price of $0.74. Whereas If you bought $1000 worth of GRI Bio, Inc. (GRI) shares 2 years ago, it would be worth $0.81 as of December 21, 2024 at a share price of $0.74.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
GRI Bio to Participate in the Virtual Investor Closing Bell Series
GlobeNewswire Inc.
Dec 06, 2024 1:35 PM GMT
Live webcast on Thursday, December 12th at 4:00 PM ET LA JOLLA, CA, Dec. 06, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) ce
GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)
GlobeNewswire Inc.
Nov 21, 2024 1:45 PM GMT
Workshop, poster and oral presentation of data given as part of the 8th Annual Antifibrotic Drug Development (AFDD) Summit Data demonstrate that NKT cells are activated in airways in IPF patients and inhibition of iNKT cell activity with GRI-0621 ame
GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024
GlobeNewswire Inc.
Oct 24, 2024 12:30 PM GMT
Proceeds from recent exercise of warrants estimated to extend cash runway into mid Q1 2025, including interim data readout from Phase 2a biomarker study of lead program, GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) Current treatm